LGND
Ligand Pharmaceuticals Incorporated
$235.41
+$6.08(+2.65%)
78
Overall
75
Value
90
Tech
71
Quality
Market Cap
$3.56B
Volume
165.17K
52W Range
$98.89 - $247.38
Target Price
$270.67
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $109.0M | $141.1M | $251.5M | $120.3M | $186.4M | $241.5M | $196.2M | $131.3M | $167.1M | $268.1M | ||
| Total Revenue | $22.5M | $141.1M | $251.5M | $120.3M | $163.6M | $241.5M | $196.2M | $131.3M | $167.1M | $268.1M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-5.6M | $-5.4M | $6.3M | $11.3M | $30.4M | $62.2M | $52.8M | $10.5M | $11.1M | $14.5M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $103.4M | $135.7M | $245.1M | $108.9M | $133.1M | $179.4M | $143.4M | $120.8M | $156.1M | $253.5M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-65.1M | $-73.0M | $-87.7M | $126.0M | $177.7M | $137.7M | $140.4M | $121.5M | $189.7M | $227.1M | ||
| Research & Development | $21.2M | $26.9M | $27.9M | $55.9M | $59.4M | $32.1M | $36.1M | $24.5M | $54.4M | $81.2M | ||
| Research Expense | $21.2M | $26.9M | $27.9M | $55.9M | $59.4M | $32.1M | $36.1M | $24.5M | $21.4M | $81.2M | ||
| Selling, General & Administrative | $27.7M | $28.7M | $37.7M | $41.9M | $64.4M | $46.8M | $70.1M | $86.4M | $78.7M | $92.4M | ||
| Selling & Marketing Expenses | -- | -- | -- | -- | -- | -- | -- | $33.7M | -- | -- | ||
| General & Administrative Expenses | $27.7M | $28.7M | $37.7M | $41.9M | $64.4M | $46.8M | $70.1M | $52.8M | $78.7M | $92.4M | ||
| Promotion & Advertising | -- | -- | -- | -- | -- | -- | -- | $33.7M | -- | -- | ||
| Salaries & Wages | $-18.9M | $-24.9M | $-20.8M | $24.5M | $30.7M | $29.3M | -- | -- | -- | -- | ||
| Depreciation & Amortization | $10.6M | $12.1M | $15.8M | $1.5M | $1.8M | $34.2M | $3.8M | $2.9M | $2.3M | -- | ||
| Depreciation & Amortization | $10.6M | $12.1M | $15.8M | $1.5M | $1.8M | $34.2M | -- | -- | -- | -- | ||
| Amortization | $10.6M | $12.1M | $15.8M | $210.4M | $595.3M | $34.2M | $139.9M | $137.0M | $138.2M | -- | ||
| Other Operating Expenses | $-70.0K | $-1.1M | $-1.2M | $-543.0K | $-3.9M | $-37.6M | $34.2M | -- | $33.0M | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $43.9M | $68.1M | $163.7M | $807.1M | $25.8M | $103.9M | $3.0M | $11.9M | $-22.6M | $41.0M | ||
| EBITDA | $30.5M | $93.9M | $274.8M | $895.8M | $70.2M | $159.5M | $89.9M | $101.1M | $41.3M | $198.7M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | $13.5M | $48.3M | $35.7M | $27.4M | $19.6M | $1.8M | $656.0K | $3.0M | $4.7M | ||
| Intinc | -- | -- | $14.0M | $28.4M | $8.1M | $886.0K | $2.0M | $7.7M | $8.1M | $13.7M | ||
| Net Non-Operating Interest Income/Expense | -- | $-13.5M | $-34.3M | $-7.3M | $-19.3M | $-18.7M | $247.0K | $7.1M | $5.0M | $8.9M | ||
| Gain on Sale of Securities | -- | $12.0K | $50.2M | $1.0M | $-16.9M | $-5.3M | $28.5M | $46.4M | $60.0M | $18.4M | ||
| Other Income/Expense | $23.7M | $-2.6M | $-43.9M | $-809.7M | $17.0M | $12.9M | $32.7M | $-46.8M | $-9.1M | $20.6M | ||
| Other Special Charges | $2.7M | $2.6M | $-6.3M | $808.6M | $-108.0K | $-7.7M | $4.2M | $-1.7M | $-20.3M | $-89.0K | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | $1.0M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Special Income Charges | $-1.0M | -- | -- | $-16.9M | $-23.4M | $-9.6M | -- | -- | -- | -- | ||
| Impairment of Capital Assets | -- | -- | -- | $16.9M | -- | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $8.0M | $70.7M | $221.6M | $832.4M | $19.1M | $91.8M | $37.8M | $64.3M | $5.6M | $163.7M | ||
| Pre-Tax Income | $8.0M | $57.2M | $173.3M | $796.6M | $-10.5M | $72.2M | $36.0M | $63.7M | $2.5M | $159.0M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $10.3M | $44.7M | $30.0M | $167.3M | $-5.3M | $-4.1M | $41.2M | $9.8M | $6.5M | $34.5M | ||
| NET INCOME | ||||||||||||
| Net Income | $-3.3M | $12.6M | $143.3M | $629.3M | $-3.0M | $57.1M | $-33.4M | $52.2M | $-4.0M | $124.5M | ||
| Net Income (Continuing Operations) | $-3.3M | $12.6M | $143.3M | $629.3M | $-3.0M | $76.4M | $-5.2M | $53.8M | $-4.0M | $124.5M | ||
| Net Income (Discontinued Operations) | $-3.3M | $12.6M | $143.3M | $629.3M | $-3.0M | $57.1M | $-33.4M | $52.2M | $-4.0M | $124.5M | ||
| Net Income (Common Stockholders) | $-3.3M | $12.6M | $143.3M | $629.3M | $-3.0M | $57.1M | $-33.4M | $52.2M | $-4.0M | $124.5M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $196.3M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-70.7M | $-78.4M | $-81.4M | $137.3M | $208.1M | $199.9M | $193.2M | $132.0M | $200.8M | $241.6M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $33.4M | $33.7M | $33.9M | $30.4M | $25.9M | $26.7M | $16.9M | $17.3M | $19.0M | $19.3M | ||
| Average Shares Outstanding (Diluted) | $33.4M | $37.6M | $38.6M | $31.7M | $25.9M | $27.6M | $16.9M | $17.8M | $18.3M | $20.3M | ||
| Shares Outstanding | $33.5M | $34.0M | $32.8M | $26.5M | $26.6M | $27.0M | $17.1M | $17.7M | $19.3M | $19.9M | ||
| Basic EPS | -- | -- | -- | $20.67 | $-0.11 | $2.15 | $-1.98 | $3.02 | $-1.64 | $6.44 | ||
| Basic EPS (Continuing Operations) | $-0.07 | $0.37 | $4.22 | $20.67 | $-0.11 | $2.15 | $-0.31 | $3.11 | $-0.22 | $6.44 | ||
| Diluted EPS | -- | -- | -- | $19.87 | $-0.11 | $2.06 | $-1.98 | $2.94 | $-1.64 | $6.13 | ||
| Diluted EPS (Continuing Operations) | $-0.07 | $0.33 | $3.72 | $19.87 | $-0.11 | $2.06 | $-0.31 | $3.03 | $-0.22 | $6.13 | ||
| OTHER METRICS | ||||||||||||
| Basic Discontinuous Operations | $0.02 | -- | -- | -- | -- | -- | $-1.67 | $-0.10 | -- | -- | ||
| Development Expense | -- | -- | -- | -- | -- | -- | -- | -- | $33.0M | -- | ||
| Diluted Discontinuous Operations | $0.02 | -- | -- | -- | -- | -- | $-1.67 | $-0.09 | -- | -- | ||
| Earnings from equity interest | $-23.1M | $-2.0M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings From Equity Interest Net Of Tax | $-23.1M | $-2.0M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Excise Taxes | -- | -- | -- | $16.9M | -- | -- | -- | -- | -- | -- | ||
| Gain On Sale Of Business | $1.1M | -- | -- | -- | -- | -- | -- | $2.1M | -- | -- | ||
| Gains Loss On Disposal Of Discontinued Operations | $731.0K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Minority Interests | -- | -- | -- | $767.2M | -- | -- | -- | -- | -- | -- | ||
| Net Income Discontinuous Operations | $731.0K | -- | -- | -- | -- | $-19.2M | $-28.1M | $-1.7M | -- | -- | ||
| Net Income Extraordinary | $-1.6M | $12.6M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Net Operating Interest Income Expense | $-12.2M | $-11.4M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gain Loss From Disposition Of Discontinued Operations | -- | -- | -- | -- | -- | $-19.2M | -- | -- | -- | -- | ||
| Other Gand A | $27.7M | $28.7M | $37.7M | $41.9M | $64.4M | $46.8M | $70.1M | $52.8M | $78.7M | $92.4M | ||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | -- | -- | -- | $30.6M | $6.2M | ||
| Other Taxes | -- | -- | -- | -- | -- | -- | $34.2M | -- | -- | -- | ||
| Other Write Down | -- | -- | -- | -- | -- | -- | -- | -- | -- | $32.7M | ||
| Rent And Landing Fees | $27.7M | $28.7M | $37.7M | -- | -- | -- | -- | $33.7M | -- | -- | ||
| Write Off | -- | -- | -- | -- | $23.4M | -- | -- | -- | -- | -- | ||
| Othspecchg | -- | -- | -- | -- | -- | $9.6M | -- | -- | -- | -- | ||
| Restruct | $1.0M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | LGND | $235.41 | +2.7% | 165.17K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Ligand Pharmaceuticals Incorporated Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW